Drug Interaction Report

Consumer information for this interaction is not currently available.

ADJUST DOSE: Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of crinecerfont, which is primarily metabolized by the isoenzyme. Concomitant use with rifampin, a potent CYP450 3A4 inducer, decreased crinecerfont peak plasma concentration (Cmax) and systemic exposure (AUC) by 23% and 62%, respectively. No data are available for other, less potent inducers. Reduced efficacy of crinecerfont may occur.

MANAGEMENT: When coadministered with moderate CYP450 3A4 inducers, the crinecerfont evening dose should be increased.
In adults, increase the crinecerfont dose to 200 mg with a meal in the evening (morning dose of 100 mg with a meal remains unchanged).

In pediatric patients 4 years of age and older, increase the crinecerfont dose based on weight:
-Patients weighing 10 kg to less than 20 kg: 50 mg with a meal in the evening (morning dose of 25 mg with a meal remains unchanged)
-Patients weighing 20 kg to less than 55 kg: 100 mg with a meal in the evening (morning dose of 50 mg with a meal remains unchanged)
-Patients weighing 55 kg or more: 200 mg with a meal in the evening (morning dose of 100 mg with a meal remains unchanged)

Consumer information for this interaction is not currently available.

ADJUST DOSING INTERVAL: Coadministration with food increases the oral bioavailability of crinecerfont. Administration of crinecerfont capsules and oral solution with a high-fat meal (800 to 1000 calories, 50% fat), increased crinecerfont peak plasma concentration (Cmax) by 4.9-fold and 8.6-fold, respectively, and systemic exposure (AUC) by 3.3-fold and 8.3-fold, respectively, compared to administration under fasting conditions.

MANAGEMENT: Crinecerfont should be administered twice daily with a meal in the morning and evening without regard to fat or calorie content.